• Korro Bio director Jean Francois Formela disclosed sales of 28,468 common shares on Aug. 19.
• Weighted average sale price of USD 14, with trades executed between USD 13.95 and USD 14.15.
• Holdings fell to 681,197 shares in one indirect position, with 141,053 shares in a second indirect position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001030575-26-000010), on August 21, 2026, and is solely responsible for the information contained therein.